Multitude
Building an ADC Development and Discovery Atlas
Multitude is a clinical-stage ADC-focused platform company founded by successful serial entrepreneurs. Multitude's competitive advantage in developing industry leading ADCs is based on two proprietary platform technologies: MabArrayTM , an antibody platform for discovering novel cell surface tumor targets to build first-in-class ADCs, and T1000, a novel linker/payload technology for developing ADCs with a highly favorable balance of bystander effect, potency, and toxicity. The powerful synergy derived from combining MabArrayTM and T1000 enables Multitude to build an atlas of ADCs that has the potential to treat malignancies with high unmet needs and achieve higher and more durable responses.
Multitude based in Shanghai and is backed by prominent investors including Northern Light Venture Capital, Co-win Ventures, Loyal Valley Capital, and M Ventures
